Figure S2.

Determination of the optimum concentration of small-molecule inhibitor treatment. (A) ASCs treated with JNJ at different concentrations (0, 125, 250, 500, 750, or 1,000 nM); (B) ASCs treated with Ro-3306 at different concentrations (0, 1.25, 2.5, 5, 7.5, or 10 µM); (C) ASCs treated with purvalanol A at different concentrations (0, 3.125, 6.25, 12.5, 25, or 50 µM). CCK8 was used to evaluate the effect of JNJ on ASC proliferation. If the same letter appears above the column of each concentration at one time point, that indicates that there was no statistical significance between those two concentrations at that timepoint. ASC, adipose-derived mesenchymal stem cell.